Joseph M. Fitzgerald serves as the Executive Vice President and Group President of Cardiology at Boston Scientific Corporation, a leading innovator of medical solutions that improve the health of patients around the world. In his role, Fitzgerald oversees the company's global Cardiology business, which includes Interventional Cardiology, Structural Heart, and Electrophysiology. He is responsible for driving the strategic direction, growth, and operational excellence of these critical business units, which play a vital role in advancing patient care and outcomes. Fitzgerald brings a wealth of experience and leadership to his position at Boston Scientific. Prior to joining the company, he held various senior leadership roles at Medtronic, another prominent medical device company. During his tenure at Medtronic, Fitzgerald demonstrated a strong track record of driving business growth, fostering innovation, and building high-performing teams. His expertise in the cardiovascular space, coupled with his strategic vision and operational acumen, have been instrumental in strengthening Boston Scientific's position as a leader in the Cardiology market. Under Fitzgerald's leadership, Boston Scientific's Cardiology business has continued to expand its portfolio of innovative technologies and solutions that address unmet clinical needs. He has been a driving force behind the company's commitment to advancing patient care through the development and commercialization of groundbreaking products, such as the WATCHMAN FLX™ Left Atrial Appendage Closure Device and the FARAPULSE™ Pulsed Field Ablation System. Fitzgerald's dedication to improving patient outcomes, combined with his ability to navigate complex market dynamics, has positioned Boston Scientific for sustained success and growth in the Cardiology space.